US equities |
TSLA $361.03 ▼-0.39% MU $896.88 ▼-3.69% NVDA $217.09 ▼-0.06% AAPL $345.94 ▲+1.15% SPCX $146.12 ▼-1.68% SNDK $1,338.40 ▼-4.05% META $721.48 ▼-2.07% MSFT $533.72 ▼-1.06%
FinancialContent

Articles published by 89bio, Inc.

< Previous 1 2 Next >
News headline image
89bio, Inc. Announces Agreement to be Acquired by Roche
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Reports Second Quarter 2025 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio to Participate in Upcoming Investor Conferences
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Reports First Quarter 2025 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio to Participate in the Leerink Partners Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Provides Business Update and Outlook for 2025
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Reports Third Quarter 2024 Financial Results and Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio to Participate in the UBS Global Healthcare Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
News headline image
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Tickers ETNB
< Previous 1 2 Next >